Trial Profile

Efficacy KB109 when added to supportive self-care for outpatients with mild-to-moderate COVID-19 disease

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KB 109 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Kaleido Biosciences

Most Recent Events

04 Jan 2021 According to a Kaleido Biosciences media release, company expects topline data from this smaller study of KB109 in the first quarter of 2021.
19 May 2020 New trial record
14 May 2020 According to a Kaleido Biosciences media release, this Study Expected to Initiate Shortly with Similar Design and Additional Microbiome Analysis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com